Astellas Pharma Inc.: R&I Affirms AA/a-1+, Stable
(WorldNews Japan)

NEWS RELEASE R&I Affirms AA/a-1+, Stable: Astellas Pharma Inc. Sep 20, 2017 Rating and Investment Information, Inc. (R&I) has announced the following: ISSUER: Astellas Pharma Inc. Issuer Rating: AA, Affirmed Rating Outlook: Stable Commercial Paper: a-1+, Affirmed RATIONALE: Astellas Pharma Inc. is a pharmaceutical company that has global products, such as prostate cancer treatment "XTANDI," immunosuppressant "Prograf" and overactive bladder treatment "Vesicare." In the domestic market, it provides many...